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Abstract 
Introduction: Malaria, a protozoal infection of human red blood cells transmitted by the 
female Anopheles mosquito, remains a considerable threat especially to pregnant women 
and children, and remains the tenth leading cause of death in Uganda. 
Methods: This mixed methods study utilized key informant interviews conducted in three 
Ugandan districts. This study described the penetration of malaria preventative strategies 
and challenges with their uptake. In addition, a retrospective analysis of de-identified data 
from the medical reports of patients from the Nyakibale emergency department (ED) located 
in western Uganda.  
Results: Results revealed the use of various interventions for malaria prevention, but also 
reported many barriers to the use of current recommended prevention strategies. Results of 
analysis of the de-identified data revealed a significant reduction in cases of malaria 
between 1/2010-12/2018 [p<0.001]. Our results also show that the burden of malaria cases 
in Uganda displayed a seasonal component with the highest number of cases diagnosed 
between November and January [p<0.001]. Finally, although several threats to Artemisinin-
based Combination Therapy (ACT) resistance were identified through key informant 
interviews, a significant reduction in the treatment of slide-negative malaria [p<0.001] and 
cases that were not tested prior to treatment [p<0.001] at Nyakibale Hospital was noted.  
Conclusion: Results revealed that community level interventions can decrease the ED 
burden of malaria although numerous challenges and barriers remain to their uptake in the 
community. We describe trends in malaria seen between 1/2010-12/2018. I addition, a 
variety of new, innovative strategies being implemented by public health officials are 
described.
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Introduction  
 
 Malaria, a protozoal infection transmitted through the bite of the female 
Anopheles mosquito, is a serious global disease caused by infection of human red 
blood cells by the plasmodium species (CDC, 2018). There are five different 
plasmodium species including plasmodium falciparum, plasmodium vivax, plasmodium 
knowlesi and two forms of plasmodium ovale (WHO, 2015). P. falciparum, the most 
prevalent in sub-Saharan Africa, is almost always the cause of severe malaria 
(Nkumama, 2017). Symptoms of malaria include headache, fatigue, muscle aches, 
fevers, and chills. Prompt diagnosis and treatment within 24 hours of onset is vital to 
preventing mortality and other complications. Delayed or ineffective treatment 
secondary to medication resistance can cause severe malaria, leading to seizures, 
coma, renal failure, anemia, pulmonary edema, bleeding, shock and death (MSF, 2017). 
Malaria is endemic in Africa, Central and South America, the Caribbean, and 
parts of Europe and the South Pacific (CDC, 2018). Currently, sub-Saharan Africa has 
the greatest global morbidity and mortality rates (Bioland, 2000). Approximately 90% of 
malaria cases occur in sub-Saharan Africa, with victims under 5 years old accounting 
for 78% of deaths caused by malaria. Children and pregnant females have the highest 
risk of acquiring the disease (WHO, 2015). Children are at higher risk due to their lower 
immunity to the parasite as they have not had as much exposure. The higher 
vulnerability seen in pregnant women has been attributed to changes in hormone levels 
and depressed immune system (Population Reference Bureau, 2001). In addition, when 
malaria occurs during pregnancy, it is more difficult to detect as the parasite can 
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sequester to the placenta resulting in false negative tests when samples are taken from 
the patient’s vein (WHO, 2015). This can lead to delays in diagnosis.  
Background  
Many interventions have been put into place to prevent and eliminate malaria. 
According to the 2014 World Malaria Report, malaria prevalence worldwide declined by 
48% and mortality decreased by 47% between the years 2000–2013 (WHO, 2015). 
Nevertheless, malaria remains a major issue in sub-Saharan Africa (Jhpiego, 2014). 
Although estimating the true prevalence of malaria in Africa is complicated, according to 
the WHO, there were 219 million reported cases of malaria in 2017 (WHO, 2019). This 
may under-represent the true case number as many people with fever do not present to 
healthcare facilities and some may self-treat assuming they have malaria. Surveillance 
data may also be imprecise according to the WHO. Finally, the registration of these 
cases may not be complete due to lack of diagnostic resources and lack of trained 
providers who treat based on symptoms rather than a confirmed diagnostic test 
(Nkumama, 2017).  
World Health Organization (WHO) recommendations for controlling malaria 
 The two principal public health goals for malaria control are to reduce 
transmission to others by rapid diagnosis and treatment and to prevent drug resistance 
(Uganda Ministry of Health [MOH], 2011). Decreasing the number of people with P. 
falciparum in their blood decreases the reservoir for the infection, thus reducing 
transmission to others. The WHO's Guidelines for the treatment of malaria recommends 
several core standards for the prevention of malaria. Early diagnosis and treatment are 
critical when patients present with fever in a malaria-endemic area. Guidelines call for 
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treatment with artemisinin-based combination therapies (ACTs) if the test is positive. If 
testing is not readily available, febrile patients with clinical signs of malaria should 
receive immediate treatment to prevent complications, and tests should be performed at 
the earliest availability. If the test returns negative, the ACT should be stopped and 
further work up for source of the fever should be initiated (WHO, 2018). 
Another preventative strategy uses Intermittent Prevention Treatment (IPT), 
which involves giving anti-malaria prophylaxis to high-risk groups including pregnant 
females, children, and those with human immunodeficiency virus (HIV) or sickle cell 
disease (SCD). WHO recommends the prophylactic treatment of pregnant females with 
sulfadoxine-pyrethamine (SP) in malaria-endemic areas at least three times during their 
pregnancy, as the parasite can become sequestered to the placenta causing false slide-
negative results (WHO, 2015). Pregnant women can harbor an asymptomatic form of 
the infection, which can increase the reservoir of P. falciparum in the community, 
leading to unfavorable birth outcomes such as low birth weight, anemia, stillbirths and 
miscarriage (Uganda MOH, 2011). In addition, in 2012, the WHO introduced 
recommendations to use seasonal chemoprophylaxis during rainy seasons to children 
residing in high prevalence areas. They recommend giving sulfadoxine-pyrethamine + 
amodiaquine to children ages 3-59 months at monthly intervals during the rainy season.  
This would be in replacement of IPT in children in these areas (WHO, 2019). Other 
control strategies include indoor spraying for mosquitos and use of insecticide-treated 
nets (Tamari, 2017). The most effective approaches have involved multiple prevention 
strategies rather than just one method (Nkumama, 2017).  
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Artemisinin-based combination therapies and resistance  
Controlling malaria and preventing deadly complications of the disease is 
dependent on rapid initiation of anti-malarial drugs. Artemisinin-based combination 
therapies (ACTs) are the current recommended treatment for malaria caused by P. 
falciparum. ACTs employ a combination of an artemisinin derivative with a second, 
longer-acting anti-malarial medication. These medications work quickly and are highly 
effective at treating the disease on an individual level, as well as reducing transmission 
on a population level, by reducing the gametocytes in the bloodstream. Malaria 
gametocytes do not cause clinical symptoms; rather, they are responsible for the spread 
of infection as they are transmitted from human host to the mosquito. The gametes 
differentiate in the midgut of the mosquito and are then spread back into a human host 
(Nkumama, 2017). Although malaria resistance to ACTs has been observed in 
Southeast Asia, such resistance has not been seen in Africa to date (Nkumama, 2017). 
According to the WHO, the use of at least two anti-malarial medicines (as is the case 
when using ACTs) will decrease the chance of an endemic area developing anti-
malarial resistance (WHO, 2018).  
Entomological inoculation rate 
 The annual P. falciparum entomological inoculation rate (Pf EIR) is an indicator 
of a community’s exposure to mosquitos infected with P. falciparum. The PfEIR, a 
measure of the infectious bites per person per unit of time, is calculated by multiplying 
the average number of Anopheles mosquito bites per person by the sporozoite rate, 
which is the percentage of the mosquito population infected with P. falciparum. The 
higher the EIR, the higher the prevalence of malaria. This measure is typically analyzed 
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annually to identify the highest risk areas and assess the impact of vector control 
methods (Shaukat, 2010).  
Seasonal variations in malaria 
 The presence of malaria varies based on season. During the dry season, the 
malaria vector, the Anopheles mosquito, goes into a hibernation state where they stop 
reproducing, thereby reducing metabolism and feeding. The onset of the rainy season 
provokes rapid reproduction, which leads to a resurgence of the mosquito population 
and increased incidence of malaria (Geshem, 2018). Describing this resurgence by 
region is important as it could dictate the best time for insecticide and larvacide 
interventions and possibly utilize seasonal chemoprophylaxis in children, as described 
by the WHO. 
Diagnosis of malaria: microscopy and rapid diagnostic tests 
Malaria is diagnosed using microscopic or non-microscopic tests (Rapid 
Diagnostic Tests, RDTs). The WHO recommends a “test before treat” policy. 
Light microscopy 
Light microscopy involves direct observation of thin and thick blood films to 
identify the presence or absence of the parasite. In addition, it allows for species 
identification and quantification of parasitemia. Although light microscopy is currently 
considered the gold standard for diagnosis of malaria, it is time consuming, requires 
training and, in low resource areas, can be limited by the lack of the availability of a 
functioning microscope and electricity (Reyburn et al, 2007). Benefits to this test are the 
low cost of consumables and high sensitivity and specificity. However, a negative test 
even by light microscopy does not always rule out malaria in endemic areas. Malaria 
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caused by P. falciparum can be sequestered in capillaries and may not always be 
visible in a specimen from a peripheral blood draw (Allan, 2006). If there is strong 
suspicion of malaria, the test can be repeated.  
Rapid Diagnostic tests (RDT) 
The RDT for malaria involves detection of parasite antigens; in contrast to 
microscopy, RDT produces only qualitative results. However, this method is quick and 
can be used by people with a basic level of training (Talisuna, 2007). RDTs have a 
sensitivity of 94–100% and specificity of 89–100%, depending on the manufacturer 
(Reyburn et al, 2007). There are several limitations of RDTs as well. First, they are 
more expensive compared to performing light microscopy. Second, technical issues 
have been observed with the tests (Talisuna, 2007). Several parasites contain deletion 
mutations of the HRP-2 genes, which encode the antigen detected by the test which 
results in false negative tests. In addition, the test can become inconclusive when the 
parasite antigen overwhelms the capture site (Reyburn et al, 2007).  
Accurate and timely diagnosis followed by rapid treatment is key to correctly 
prescribing medications and preventing complications of the disease. In a study 
assessing the accuracy of prescribing patterns in febrile patients in Tanzania, Reyburn 
et al. found that 51–54% of cases that tested negative were given anti-malaria 
medications anyway (Reyburn et al, 2007). Overprescribing anti-malarial medications to 
those with negative test results not only increases the threat of ACT resistance, but 
suggests that providers may be missing other diagnoses causing fever in these 
patients. It might be expected that the availability of more RDTs might reduce the 
  7 
practice of over-prescribing anti-malarial medications. However, Reyburn et al. (2007) 
found no difference in prescribing patterns whether providers used RDTs or microscopy. 
Malaria in Uganda 
Malaria remains a major public health issue in Uganda as it is endemic to 95% of 
the country and is the tenth leading cause of death in the country (World Life 
Expectancy, 2019). Uganda has the third highest number of P. falciparum cases in sub-
Saharan Africa. Throughout Uganda, malaria causes 34% of outpatient visits and 37% 
of hospital admissions (President’s Malaria Initiative, 2017). In fact, the Apac district in 
northern Uganda has the highest entomological inoculation rate in the world (Fatunmbi, 
2018). The districts in the southwest region have experienced reduced prevalence of 
malaria while northern region districts continue to have higher incidence (National 
Malaria Control Program, 2018). 
Between 2009–2014, indoor residual spraying in 11 districts caused a significant 
reduction in the prevalence of malaria, from 42% to the current prevalence of 19%. 
According to the 2017–2018 Malaria Annual Report, prevalence has remained steady 
(~19%), with 191/1000 confirmed malaria cases. However, as of 2016, malaria 
prevalence in children in Uganda is reported at 30%. The mortality rate is at 9 
deaths/100,000 people, which is a 52% reduction since the 2016/2017 annual report 
and accounts for 5% of deaths in Uganda (Uganda MOH, 2019). 
Health system in Uganda: 
The country is divided into 127 districts, each headed by a “local council”. The 
districts are further subdivided into sub-counties, which are further divided into parishes. 
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Each parish is comprised of several villages, each housing ~50–70 households where 
250–1000 people reside (Kavuma, 2009). 
Uganda has a decentralized healthcare system, and the MOH oversees both 
public and private sectors. The private sector includes private health practitioners 
(PHPs), private not-for-profit (PNFPs) and traditional medicine practitioners. The public 
realm includes National Referral Hospitals, which serve populations upwards of 30 
million people, and Referral Hospitals, which serve ~2 million people from many 
districts. In addition, there are district level health services and Health Centers at the 
lower levels. Health Center III facilities serve at the sub-county level, Health Center IIs 
serve at the parish level, and Health Center Is serve at a village level. In addition, 
Village Health Teams provide screening and education within the village (Mukasa, 
2012). 
National Malaria Control Program in Uganda  
The National Malaria Control Program in Uganda guides malaria prevention in 
the country based on the Uganda Malaria Reduction Strategic Plan, which was updated 
in 2011 and 2018. The strategic plan calls for providing integrated vector management 
to 85% of the country and ensuring proper utilization of the methods with the objective 
of reducing malaria morbidity by 80%, malaria prevalence by 85% and morbidity to 
1/100,000 people by 2020 (Uganda MOH, 2019). The policy outlines Uganda’s malaria 
prevention methods based on six key strategic objectives: integrated vector 
management, diagnosis/case management, health promotion, program 
management/collaboration, surveillance/research, and emergency epidemic 
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preparedness (Uganda MOH, 2019). The specific policies recommended by the MOH 
through the National Malaria Control Program (Uganda MOH, 2014) are outlined below. 
1. Rapid diagnosis 
The National Malaria Control Program recognizes the implications of 
misdiagnosis of malaria and recommends diagnosis with either a light 
microscopy or RDT if microscopy is unavailable before treatment for 
malaria. Malaria treatment initiated without confirmation poses a 
potential risk for ACT resistance in the area (Uganda MOH, 2011).  
2. Rapid treatment with ACT 
In 2000, the MOH in Uganda revised treatment recommendations to 
recommend a combined treatment with chloroquine and 
sulfadoxine/pyrimethamine, as treatment failure with a single anti-
malarial medication was being recognized. However, between 2002 
and 2004, increasing treatment failure to this combination of 
medications was noted; therefore, recommendations in 2004 were 
updated to use ACT for first line treatment of uncomplicated malaria 
and intravenous artesunate for severe or complicated malaria (Uganda 
MOH, 2011) 
3. Vector control 
For mosquito control, the policy recommends using integrated vector 
management, which employs multiple strategies to control the 
mosquito population carrying the malaria-causing parasite. The policy 
calls for universal coverage of the population with a long-lasting 
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insecticidal nets (LLIN) advocating for one net per two persons. 
Second, the policy recommends using indoor residual spraying 
insecticides and larvacide as well as performing intermittent tests for 
mosquito resistance to these products to inform the choice of 
insecticide (Uganda MOH, 2011).  
4. Intermittent preventative treatment (IPT) 
The MOH in Uganda recommends IPT for malaria during pregnancy 
with sulfadoxine/pyrimethamine (SP). Recommendations prior to 2017 
were to give at least three doses, one month apart starting in the 
second trimester. In December of 2017, recommendations were 
increased advocating to give pregnant women SP monthly starting 
after 13 weeks. 
5. Surveillance and research 
The National Malaria Control Program describes the government 
intentions to strengthen malaria surveillance by creating a system for 
mapping hard-to-reach and high-risk populations and to improve 
communication and distribution of information about these preventative 
methods to the public (Uganda MOH, 2018). In addition, they have 
developed a tracking program to ensure implementation of malaria 
prevention strategies with the aim of developing policies based on 
evidence-based research (Uganda MOH, 2011). Finally, entomologic 
indicators, as described above, are utilized to assess mosquito 
infectivity (Uganda MOH, 2011). 
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Challenges and Barriers to Prevention of Malaria 
Despite these existing guidelines, malaria remains a major public health issue for 
Uganda, stressing the importance of identifying barriers and challenges for using these 
strategies. According to the 2016 Uganda Demographic and Health Survey, which 
interviewed 18,506 women (15–49 years of age) and 5,336 men (15–54 years of age) in 
19,588 households sampled, 78% owned at least one insecticide treated net, which was 
a significant increase from 16% in 2006 (DHS Uganda, 2016). However, only 55% of 
interviewees stated that they utilized the LLINs for sleeping. Among the most 
vulnerable, 70% of pregnant females and 67% of children reportedly slept under LLINs. 
The survey investigated the use of IPT in pregnancy, reporting that 75% of pregnant 
females interviewed took at least one dose of preventative anti-malarial medicines, 
while only 17% took the recommended three doses. Interestingly, the prevalence of 
malaria was lower and the use of LLINs and IPT was much higher between 2014–2015 
(DHS Uganda, 2016). 
Maslove et al. (2009) conducted a systematic review of 39 research articles that 
assessed beliefs about causes of malaria and prevention in sub-Saharan Africa. They 
found most of the studies were performed in rural areas and almost all concentrated on 
barriers in malaria prevention in childhood. Major barriers identified included lack of 
education and reliance on cultural beliefs, such as using herbal tea or wearing charms, 
which were ineffective at preventing malaria. There was also a lack of knowledge in 
regard to transmission of malaria, beliefs that it could not be prevented and belief in the 
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use of traditional remedies instead of using anti-malarial medications. Some had 
mistrust of the anti-malarial medications. Other system barriers included financial issues 
for medications or mosquito nets and lack of accessibility to a healthcare facility 
(Maslove et al, 2009).  
Kokwaro (2009) assessed challenges to the diagnosis and treatment of malaria 
and found that the major barriers included parasite resistance to medications such as 
chloroquine, sulphadoxine-pyrimethamine, amodiaquine, mefloquine and quinine. Also 
described was difficulty of administering these medications to infants and children. He 
also found that time to diagnosis and treatment was a barrier to prevention and 
suggested that further education was needed for healthcare workers and the community 
(Kokwaro, 2009).  
Thiam et al. (2013) assessed system barriers to use of intermittent preventative 
treatment in pregnancy in Sub-Saharan Africa and found the primary issues to be lack 
of funding, lack of provider knowledge of ITP, supply chain issues, low accountability 
and difficulty of patients obtaining transport to healthcare facilities for prenatal care. 
Research Aims 
While progress has been made in addressing malaria over the last decade in 
Uganda, more needs to be done to meet the goals of the presidential commission. This 
thesis utilized a mixed methods research design generating both qualitative and 
quantitative data to assess trends in malaria, prevention measures currently in use and 
to identify what barriers still exist in prevention of malaria.  
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Specifically, this thesis aimed to: 1) identify current prevention strategies actively 
being used in Uganda and gain insight on the degree of acceptance of these strategies 
in the community; 2) identify challenges with the uptake of these preventative strategies 
in the community; 3) identify solutions to close the gaps between Ugandan policy 
recommendations and current practice; 4) identify potential threats to ACT resistance; 
and 5) describe trends in malaria seen in an emergency department (ED) in western 
Uganda over an 8 year time period. 
 
Methods 
This study analyzed ED records obtained from the Nyakibale Health Center ED 
located in rural western Uganda combined with key informant interviews in western 
Uganda. Since southwest Uganda has seen an overall improvement in the prevalence 
of malaria over the past decade, it becomes an interesting area to understand both the 




Karoli Lwanga “Nyakibale” Hospital, located in the Rukungiri district in southwest 
Uganda, is a rural, private, nonprofit community hospital. The hospital has 
approximately 300 beds and provides emergency, medical, surgical, orthopedic, 
pediatric, and obstetric/gynecological services. This hospital has a catchment area of 
over 180,000 people, of whom roughly half are under age 20 years (Global Emergency 
Care, 2018).  
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Qualitative Methods 
Key informant interviews were conducted with community health workers, 
nurses, malaria prevention outreach workers, practitioners including midwives, medical 
officers and emergency care practitioners, medical officer district team leaders, and 
WHO officials. These interviews were conducted to gain an understanding of the current 
malaria prevention strategies being used and to identify barriers that may hinder 
execution of these strategies. We searched for potential gaps between policy 
recommendations and current practice. We assessed community risk factors that may 
lead to ACT resistance in the future. A total of 17 interviews were performed at seven 
different facilities located in the districts of Masaka, Mpigi and in Kampala. The goal was 
to speak to a variety of key informants to gain different perspectives. 
We interviewed a variety of key informants (Table 1 in Appendix 2) in western 
Uganda in February 2019 utilizing semi-structured interview questions (included in 
Appendix 1). We utilized an open coding system for qualitative analyses to describe the 
penetration of malaria preventative strategies in the community, identify challenges with 
the uptake of these preventative strategies, and identify solutions to close gaps between 
recommendations in the Malaria Control Strategy Policy and current practice within the 
communities of western Uganda.  
Quantitative Analysis  
Data were extracted from the records of all patient visits in the Nyakibale Hospital 
Emergency Department (ED) from 11/2009–12/2018 and analyzed using Stata 15.1 
(Stata Corp, College Station, TX). Given only 2 months of data were available in 2009, 
this data was excluded.  We assessed whether the implementation of public health 
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measures was reflected in the ED burden of malaria. The major districts served by this 
hospital included Rukungiri, Ntungamo, Kanungu, Rakai, Mitooma, Mbarara, Masaka, 
and Mpigi among others. Nyakibale Hospital primarily used microscopy, rather than 
RDT’s, to diagnosis malaria, thus slide-negative and slide-positive malaria were the 
outcome variables used to indicate the presence of malaria. 
To assess trends in incidence of malaria over time, the data were stratified by three 
phases: baseline phase (1/2010–12/2013), the first intervention phase (1/2014–
12/2017), and the second intervention phase (1/2018–12/2018). These phases were 
chosen based on results from our key informant interviewees who discussed the 
initiation of interventions at the start of these phases. In 2013, updated national 
guidelines called for the use of IPT in pregnant women and recommended that pregnant 
women receive at least two doses of sulfadoxine- pyramthamine (SP) during their 
pregnancy. The first intervention phase (1/2014–12/2017) occurred at the beginning of 
the universal distribution of LLINs, and the second intervention phase (1/2018–12/2018) 
coincided with guideline changes to increase the frequency of IPT in pregnant women 
(given monthly after week 13). There was some uncertainty among key informants of 
whether IRS was used in this area as well around 2013-2014 but these reports could 
not be confirmed. Pearson’s chi squared analysis was used to assess for trends in 
incidence between the three phases.  
In addition, we assessed trends in mortality secondary to malaria over time 
between 11/2009–12/ 2018. Pearson’s chi squared analysis was used to identify 
differences in case fatality rate (CFR) between years. Relative risk reduction was 
analyzed (calculated by the absolute risk difference * number of patients/year * case 
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fatality rate) between the baseline phase and first intervention phase and between the 
first and second intervention phases. 
To identify a potential role for seasonal chemoprophylaxis in children, we 
assessed the results of malaria microscopy tests with respect to month to investigate 
seasonal variations in the incidence of malaria. Data extracted from patient records 
between 12/2010–12/2018 were grouped together by month. Once again, data from 
11/2009-12/2009 when collection was started was excluded to avoid skewing the data 
towards the months of November and December.  Pearson’s chi squared analysis was 
used to identify differences between months.  
Finally, with the recent concerns related to ACT resistance and the WHO 
guidelines of “test prior to treating”, we assessed trends in prescribing patterns over 
time to determine whether providers from Nyakibale Hospital were following the “test 
prior to treatment” recommendations. We utilized chi squared analysis to assess the 
number of cases treated with a prescription for an anti-malarial medication despite 
having a negative microscopy test over time. We also used chi-squared analysis to 
assess the number of cases treated for malaria in patients who had not been tested for 
malaria to assess for trends over time.  
Ethical Considerations  
Prior to initiation, this research proposal was reviewed by the Institutional Review 
Board at the University of Connecticut and deemed to be exempt from review given no 
personal questions were asked of key informants and the quantitative data analyzed 
was previously de-identified. 
Results: 
 
  17 
Qualitative Results: 
 
Malaria prevention strategies employed in western Uganda: 
 
 The following results are separated into community level responses and 
governmental level responses. The key informants contributing to the community level 
responses include members of village health teams, malaria outreach workers, nurses, 
midwives, medical officers, physicians and practitioners that practice in the community. 
Key informants contributing to the governmental level responses include district leaders 
and public health officials who worked for the WHO.  
 
Community level: 
The first prevention method noted by every key informant interviewed from the 
community was use of LLINs, which have been distributed by the government every two 
years since 2014. The majority of interviewees estimated that approximately 70% of 
community members use the LLINs.  
IPT with sulfadoxine/pyrimethamine (SP) during pregnancy was the second most 
common prevention technique employed. Since December 2017, the Ugandan MOH 
has increased recommended frequency of IPT to monthly doses starting at 13 weeks. 
Compliance was not well known as key informant estimates ranged between 50–100% 
of pregnant females. IPT is also given monthly to patients with sickle cell disease, but 
compliance was not known by the key informants interviewed. 
Other common prevention strategies utilized include community education, clearing 
around homes and rapid diagnosis/treatment. Teams of nurses and community health 
workers called “ready home teams” or “village health teams” are deployed in the villages 
to identify people who have fever. RDTs are used to test individuals with fever and, if 
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positive, Artemether + Lumefantrine (the most common ACT used in this area) is given 
twice daily for three days. They also educate the community residents to present early 
to the health center with any signs of malaria for rapid diagnosis with microscopy or 
RDTs. In addition, they refer pregnant females to the clinics to receive the above-
mentioned IPT as well as education directed at maintaining cleanliness in the area 
surrounding the homes. They recommend slashing bushes around the homes, keeping 
trash to a minimum, and clearing stagnant water by filling in holes and pouring motor oil 
over remaining stagnant water to kill mosquitos. They educate the community to close 
their doors at dusk and install wire mesh (screens) over the windows to keep mosquitos 
out of the home. Furthermore, community members build fires to create a layer of 
smoke around their homes and plant “Omuteete”, a citronella-like plant, to keep 
mosquitos away.  
Strategies that have not been employed include IPT for school age children or 
seasonal chemoprophylaxis. In addition, there is little to no use of indoor residual 
insecticide spray in western Uganda. Two key informants reported that areas 
surrounding Rukungiri were sprayed between 2013-2014 but stopped. Key informants 
estimate 0–30% of households utilize IRS in their homes, but only if they can afford it. In 
addition, personal repellent use is very low, with estimated use between 0–20% of the 
population. 
Governmental level 
According to public health officials, the government has a variety of malaria 
prevention initiatives. The government level policies and guidelines are based on the 
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Uganda Malaria Reduction Strategic Plan 2014–2020, with the 2020 goal to reduce 
prevalence of malaria from 19% to 7%.  
For integrated vector management, the “Indoor Residual Spraying Project” was 
initiated in 2009 in 11 Ugandan districts where prevalence is highest. Unfortunately, it 
was discontinued in 2014 due to lack of funding. However, when the mid-review of the 
Uganda Malaria Reduction Strategic Plan was performed in 2017, a resurgence of 
malaria was noted throughout the country, especially in the north. Therefore, the 
“Continued Indoor Residual Spraying Project” was re-initiated with spraying in another 
15 districts starting in northern Uganda.  
The use of larvacide is currently being piloted in three districts. Larvacide is a 
type of insecticide that targets larvae before they develop into adult mosquitos (EPA, 
2016). 
In 2016, surveillance was introduced as a core intervention as well as utilizing 
both epidemiologic data and the entomological surveillance (or EIR) described above. 
Entomologic training was conducted for 35 vector control officers in 23 districts. 
Although LLINs were distributed in 2014–2015, the first Universal Coverage Campaign 
was introduced in 2017, which called for 100% of households to own a LLIN. A total of 
26.5 million LLINs have been distributed, and it was estimated that over 95% of 
households should own at least one net, but it is estimated that 70% of the population 
use them. 
A majority of districts utilize Integrated Community Case Management with a goal 
of at least 90% of cases receiving prompt diagnosis and treatment. Efforts include 
education of practitioners and village health teams, quality control of diagnostic tests 
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and ensuring availability of anti-malarial medications. They encourage the “test before 
treatment” policy as is recommended by the WHO.  
A policy also exists to promote IPT during pregnancy. Prior to December of 2017, 
it was recommended that pregnant women receive at least three doses throughout their 
pregnancy but policy recommendations changed at this time recommending IPT be 
given monthly starting at week 13. In 2018, close to 70% of females received two or 
more doses of IPT during pregnancy, which was up from 57% in 2016 (MOH, 2019). 
The Mass Action Against Malaria plan, recently approved by the President, is the 
newest initiative being employed, which uses high burden–high impact methods with a 
goal to reach every household in Uganda. It calls for malaria prevention accountability 
at multiple levels starting at the head of each household, village health teams, schools, 
parishes at health centers, sub-counties and finally up to the district level. Messages on 
key malaria prevention strategies are being publicized through village health teams, 
religious leaders, social media, television and radio. Information on malaria prevention 
is even being disseminated through music, theater and dance. 
Key informants also noted strategies that have not been employed in Uganda. 
First, IPT has not been implemented for school-age children (5-15 years old), but this 
may be a possible strategy in the future. In addition, seasonal chemoprophylaxis is not 
used in Uganda because of the lack of clearly demarcated seasons as seen in other 
countries.  
 
Barriers and challenges to malaria prevention strategies: 
 
The key informants noted many challenges to the adoption of malaria prevention 
strategies in the community. Although the nets are typically distributed by the 
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government free of charge, health workers reported supply chain issues as well as lack 
of funding for distribution once they are received. The nets were known to tear easily 
and could not be easily replaced at times. Although most families own a LLIN, due to 
sleeping arrangements, several members of the family are often left outside the net. 
Teenage males are the group noted to most often be left outside the nets, as they are 
supposed to be “tough”. In addition, community members stated they will not use the 
nets as they feel they are too hot, have an unpleasant odor, and make it difficult to 
breathe. Some community members will not use them because of concerns about being 
allergic to the permethrin treatment. Some community members distrust the intentions 
of the government in giving them free nets and believe they are targeting their capacity 
to reproduce. Also, most people sleep on the floor and when the nets are hung, they are 
often too short to reach the floor leaving gaps for mosquito entrance. On occasion, the 
nets are used for other purposes, such as keeping gardens or chickens enclosed or for 
fishing. Finally, the color of the nets has been a barrier to their use. For example, in 
2017, the government distributed nets that were blue, which was the color associated 
with the Forum for Democratic Change political party, and those against the party would 
not utilize the nets.  
 Key informants noted several barriers for IPT use in pregnant females and 
patients with sickle cell disease. First, many patients have difficulty obtaining 
transportation to the clinics for monthly prophylaxis. Second, many are allergic to sulfa 
drugs and SP, the medication used, is a sulfa derivative. In addition, with the recent 
change in policy to expand the number of prophylactic doses given in pregnancy, clinics 
have run out of SP, especially at the year’s end. Finally, several nurses noted that if not 
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directly observed, many patients will not take the medication as they distrust the 
reasons they are being given the medication. 
 Although the WHO recommends the use of indoor residual insecticide spray in 
conjunction with LLINs as part of integrated vector management, cost of the spray is a 
substantial barrier, leaving much of the country without this prevention strategy. 
According to key informants in the government, indoor residual spray helped reduce the 
overall prevalence of malaria in the country after it was performed between 2009–2014. 
However, funding ran out, followed by a resurgence of malaria.  
 There are several barriers with regard to the use of rapid diagnosis and 
treatment. Although there is typically a good supply chain for RDTs, microscopy is more 
difficult as it requires trained laboratory technicians, which are in short supply. 
Additionally, most clinics lack power, and the microscope can only be used with natural 
sunlight on a bright day that is not cloudy or rainy. 
 Many community members might delay seeking care or attempt self-treatment 
with over-the-counter or expired anti-malarial medications. It was reported that some 
community members believe that their body will fight off the malaria and they do not 
need medications to get better. 
According to public health officials, providers still do not always follow “test and 
treat” policy, particularly among private providers.  Retention of providers trained about 
malaria guidelines was reported to be an issue, thus requiring training to be almost 
continuous. 
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 Key informants stated that it is difficult to obtain reliable and valid data resulting 
in inaccurate incidence reporting. Surveillance data, including community environmental 
indicators, which could be important in developing solutions, were lacking.  
 Educating the community comes with its own challenges. Although there is an 
abundance of written materials on malaria, it is not translated into all of the local 
languages, which is problematic as over 40 different languages are spoken in Uganda. 
Village health teams provide the primary mode of distributing education in the 
community, however, these important groups are underfunded. Not only has there been 
a decline in the number of village health teams, but money for training and materials 
has been reduced, as well.  
  Community residents found it difficult to follow environmental prevention 
recommendations such as using smoke to keep the mosquitos away, closing doors and 
windows at dusk and reducing stagnant water. The smoke causes poor air quality 
making it difficult to breathe. Uganda also has a hot climate, with average temperatures 
in the 90s during the dry season, which is a barrier to closing windows and doors. 
Furthermore, the prevention strategy employing pouring motor oil on stagnant water is 
an environmental pollutant and can cause harm to wildlife and humans alike.  
Threats to ACT Resistance 
 
 The community key informant interviews revealed several threats to the potential 
risk of ACT resistance. They estimated that 10–20% of malaria patients fail to complete 
their entire treatment regimen. When patients start to feel better (usually at treatment 
Day 2), they typically stop taking the drug and may save the pills for future use if they 
again develop a fever. This early cessation leads to a second problem in that 
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community members might self-treat or provide medication to their family members if 
they develop a fever without obtaining a diagnostic test, sometimes using expired 
medication from a previously half-treated course. Thirdly, ACT medications are sold 
over-the-counter at local drug stores. One key informant said that community residents 
often either over- or under-dose themselves when they self-prescribe. Finally, some 
practitioners noted that even with a negative RDT or microscopy test, if a patient has 
clinical signs of malaria and no other obvious source of infection, they will treat with both 
anti-malarial medications and antibiotics until the test can be repeated.  
 The Therapeutic Efficacy Study (TES) is a technique designed by the WHO to 
evaluate the use of antimalarial drugs and determine local resistance. Patients with 
diagnosis of malaria are given medication under supervised conditions and results of 
microscopy are assessed at days 28 and 42 to assess for relapse (WHO, 2018). 
According to governmental level key informants, TES was conducted in Uganda 
between 2013–2014 using the WHO protocol and found no signs of ACT resistance. 
Another study is currently in process. 
Quantitative Results:  
 
a. Trends in incidence of malaria 
 
The total number of ED patients seen at Nyakibale Hospital in the baseline phase 
(01/2010–12/2013) was 20,303 patients. Of these, 19.5% [95%CI 18.9–20.0] had a 
positive microscopy slide for malaria. The total number of ED patients seen in the first 
intervention period (1/2014–12/2017) was 21,943. Of these, 8.57% [95%CI 8.20–8.94] 
had a positive slide during this time period. The total number of patients seen in the ED 
in the second intervention phase (1/2018–12/2018) was 5,186. Of these, 1.95% [95%CI 
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1.57–2.32] had a positive slide for malaria during this time period. Overall, these data 
showed a significant reduction in case rates over time [p< 0.001]. 
 




b. Trends in mortality 
 
The CFR for a positive malaria slide by year on average was found to be 2.89% 
[95%CI 2.47–3.31]. Although significant differences occurred amongst years (p=0.024), 
there was no consistent trend in the CFR changes (See Figure 2 below); thus, the mean 
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Figure 2: Three-day mortality for malaria cases by year (1/2010–12/2018) 
 
The relative risk ratio for being diagnosed with malaria between the baseline 
phase and the first intervention phase was 0.44 (p<0.001). This relative risk reduction 
equates to roughly 606 cases of malaria and 17 malaria deaths averted per year during 
the first intervention phase. 
The relative risk ratio for being diagnosed with malaria between the first and second 
intervention periods was 0.23 (an absolute risk difference of -6.61%, p<0.001). This 
relative risk reduction equates to roughly 343 cases of malaria and 10 malaria deaths 
averted per year during the second intervention phase. 
 
 
c. Trends with respect to season 
 
The total number of malaria cases in 1/2010–12/2018 were combined and stratified 
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confirmed cases per month, and varied significantly by month. When all years were 
combined, the highest monthly incidence was found to be in January and the lowest 
was in September (Chisq = 84.08; p<0.001). 
By looking at total cases combined across all years (Figure 3), there is evidence that 
the burden of malaria cases displays a seasonal component. The highest numbers of 
cases were diagnosed between October–January, with a smaller peak from June–
August. The lowest numbers of cases were noted in February–March, with another 
relative dip in total cases in September.  
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The data showed a significant reduction in provider-issued prescriptions to 
patients with slide-negative malaria over time; initial rates of 11.2% in 2010 
decreased to current rates of 6.7% in 2018 [Chisq =63.5789; p<0.001] (Figure 4).  
 
Figure 4: Treatment of patients with anti-malarial medications with negative malaria slide 
 
 
The data also showed a significant reduction of provider-issued prescriptions to 
treat patients without first obtaining a malaria test (Figure 5); the rates decreased from 
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Figure 5: Treatment of patients with anti-malaria medications without testing 
 
Bridging the Gaps between Policy and Practice 
Finally, it is important to identify and describe the innovative solutions district 
leaders have taken in areas with a declining malaria prevalence. These observations 
can be valuable to other communities around the world dealing with similar challenges.  
One important solution that has been implemented has been establishing 
mechanisms for communication between health care providers and public health 
officials. Providers in the district of Mpigi, for example, are enrolled in a Short 
Messaging Service (SMS) system. When there are data quality issues, spikes in malaria 
incidence, inappropriate treatment or other issues, a message is sent through the 
system to the provider. In addition, if the district notes an issue in the supply chain of 
medications, RDT’s or other supplies, they can message each health center to obtain 
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meetings with village health teams and providers from health centers have been 
implemented for education and distribution of prevention material.  
Areas with poor malaria indicators are visited regularly to discuss community use 
of prevention strategies. Public health officials have targeted and educated local council 
leaders who are elected and well respected in the villages to spread the message of 
malaria prevention. Key informants said that misuse or repurposing of LLINs is no 
longer being tolerated. In fact, in one area interviewed, misuse of nets has become 
illegal. In addition, key informants reported new promotion strategies using musicals to 
spread messages on malaria prevention, quarterly bulletins with performance data and 




Uganda has made major headway in the implementation of malaria prevention 
strategies in the community, with a remarkable reduction in malaria from 42% in 2009 to 
19% in 2019 (Uganda MOH, 2019). Understanding current challenges and barriers 
facing both the government and local communities in their implementation of malaria 
prevention strategies is critical to devising suitable solutions to combat malaria. 
According to key informants, major malaria prevention strategies used in Uganda 
include promotion of rapid diagnosis and treatment, use of village health teams and 
healthcare workers for malaria prevention education, IPT for pregnant women and 
patients with HIV and Sickle Cell Disease, distribution of LLIN’s, use of IRS and 
promotion of environmental cleanliness.  
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A summary of the major barriers was lack of funding to support village health 
teams and IRS, inaccurate and missing surveillance data, failure of distribution of 
educational material in the local language, and misuse of prevention strategies in the 
community. In addition, lack of adherence by community members to prevention and 
treatment guidelines continues to remain a major barrier, including presenting early to a 
clinic at the onset of fever, failure to use prevention methods in their homes and not 
completing the full course of ACT.  
Retrospective analyses of de-identified data obtained from the Nyakibale 
Hospital ED between 2010 and 2018 showed a marked reduction in positive cases 
between 2013 and 2014. This correlates to the year the national guidelines were 
changed to treat pregnant women with at least doses of SP (IPT) during pregnancy. In 
addition, in 2014, the universal coverage campaign began to distribute long lasting 
insecticide treated nets throughout the country.  While we found no significant trends in 
case fatality rate over time, the significant reduction in cases seen in the ED (relative 
risk ratio = 0.44, p<0.001) between the baseline (1/2010–12/2013) and first intervention 
phase (1/2014–12/2017) meant that an estimated 606 cases of malaria and 17 malaria 
deaths were averted per year. Additionally, the second intervention phase (01/2018 – 
12/2018) was seen to further reduce the relative risk of malaria (relative risk ratio = 0.23, 
p<0.001) when compared to the reduced risk in the first intervention phase, and an 
additional 343 cases of malaria and 10 malaria deaths were averted in the year 2018. 
Our data showed a significant difference with respect to season. The burden of 
malaria cases displayed a significant seasonal component, with the highest number of 
cases diagnosed between November and January. This result is likely related to the 
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dichotomy between the rainy and dry seasons. Uganda has two rainy seasons, one 
from April to May and one from September to November. September marks the onset of 
the rainy season in which rapid reproduction and resurgence of the mosquito population 
occurs leading to a rise in the incidence of malaria seen in the fall and winter. Uganda 
does not currently employ the use of seasonal chemoprophylaxis in children, as is done 
in other countries. Our results suggest this strategy may be a valuable prevention 
strategy.  
Finally, key informant interviews revealed several threats to the potential risk of 
ACT resistance, including provider treatment of slide-negative malaria or treatment 
without being tested, patient failure to compete treatment regimen, and self-treatment 
with ACT medications bought over the counter. Despite these reports, the results of our 
quantitative analyses revealed a significant reduction of provider treatment of slide-
negative malaria and presumptive treatment of malaria without testing at Nyakibale 
Hospital.  
Future Recommendations: 
Based on these findings, we make the following future recommendations in 
combatting malaria in Uganda. First, we recommend more frequent distribution of 
LLINs, of neutral color, to prevent the use of old nets and to assure that all family 
members have access to their own net. We recommend distribution of educational 
material regarding proper use and reason for use of LLIN’s in the local language in 
conjunction with the nets. Second, we recommend continued education for providers 
through quarterly meetings. These meetings could also be used to distribute 
educational materials, LLIN’s, RDT’s, and medications from the district leadership to the 
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local healthcare facilities taking out the need for additional funding for transport of these 
goods. Third, we recommend investing in indoor residual spraying with both insecticide 
and larvacide to be done in all areas of Uganda. Fourth, entomologic evaluation to 
assess for infectivity and for mosquito resistance to the insecticide should be performed 
regularly. Fifth, we recommend monitoring of providers to assure the practice of the 
“test before treat” recommendations to prevent misuse of anti-malarial medications that 
might increase the risk of resistance in sub-Saharan Africa, as currently seen in Asia 
(Nkumama, 2017). Continued regular communication to address challenges to malaria 
prevention should be maintained among village health teams, health centers, 
subcounties and district medical leaders, with supporting regular visits from 
governmental actors and implementing partners. We also recommend the consideration 
of seasonal chemoprophylaxis in children in highly endemic areas during the months of 
November through January. Finally, we recommend malaria education delivery to the 
community be done in more modern ways. For example, given the fact that many 
community members own smartphones, distribution of prevention messages through 
radio, television, billboards, and social medial utilizing Facebook, Instagram, and 
what’s-app may have more utility. In addition, other creative ways to disseminate 
information about malaria prevention could be used through theater, dance and popular 
music.  
Limitations: 
 There were several limitations to this study. First, the key informant interviews 
could only be conducted in western Uganda. It would have been helpful to compare 
these findings to the perceived barriers in communities in northern Uganda where the 
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prevalence of malaria is higher. Second, key informants, although they were 
knowledgeable about malaria prevention throughout the entire country, were only 
interviewed in Kampala, Mpigi and Masaka. The quantitative data was obtained from an 
ED in Rukungiri district, located several hours from where key informants were 
interviewed. In addition, this study would have more depth if a larger number of district 
health officers could be sampled as they play a major role in development of new ideas 
for prevention material distribution and education. Finally, comparing districts according 
to statistics regarding malaria prevalence would be valuable but these data were not 
able to be obtained for this study. Despite these major limitations, documenting the 
challenges and solutions to the implementation of malaria prevention strategies in these 
few districts may help other communities overcome similar barriers.  
 
Future Research: 
We also recommend that further research be performed. The risks and benefits 
of eliminating the availability of over-the-counter anti-malarial medications should be 
investigated. While eliminating this availability may reduce the risk of ACT resistance, it 
might lead to unintended consequences of causing a resurgence of malaria cases in 
populations with limited access to medical care.  
In addition, further studies are needed on use of IPT and seasonal 
chemoprophylaxis in school-aged children. Staedke et al. (2018) reported that the use 
of IPT in children in Jinja, Uganda may have had a role in reducing the prevalence of 
malaria. However, data was only significant for children between the ages of 5–15 years 
old with the malaria prevalence from 32.8% in the control group compared to 24.9% in 
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the intervention group. No significant difference was found in those younger than five or 
older than fifteen years old. In addition, the authors found no difference in parasitemia in 
the intervention and control communities, measuring 5.1 and 5.3%, respectively 
(Staedke, 2018). The potential benefits of IPT should be compared with the risk of 
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Appendix 1 
Interview Questions  
Public Health Officials  
• Describe the public health measures put into place to reduce the prevalence of malaria? 
• When were the policies developed and initiated? 
• Do you feel the communities have adopted these measures? When do you think this occurred? 
• How does surveillance work to see if these policies are making a difference in prevalence of malaria?  
• What percentage of the population is estimated to have LLIN’s? 
• What percentage of pregnant and lactating females are receiving prophylactic malaria treatment? 
• What areas are utilizing seasonal chemoprophylaxis against malaria?  
• Do you have any additional comments on the topic? 
• How do you feel about outcomes of delivery? 
 
District Medical Officers 
• What local public health measures have been taken to reduce the prevalence of malaria? 
o When were these public health measures implemented in your district? 
o How has this been done? (How do you bridge the gap between the policies recommended by the 
government and the local community)? 
o What barriers or challenges have you found with bridging this gap? 
• Have the communities you serve have adopted the following preventative strategies? 
o Use of long-lasting insecticide treated nets 
o Integrated Vector Management: including both use of insecticide treated nets and indoor residual 
insecticide spray 
o Seasonal chemoprophylaxis for malaria 
o Intermittent preventative treatment (IPT) for pregnant females? Children?  
• Do you feel there is widespread adoption in your area? How has the community reacted to these measures?  
• How do you measure the outcomes of these preventative measures? 
• What are some of the challenges with the uptake of these preventative strategies in the community? 
• With emerging ACT resistance in other areas of the world, do you feel like providers are following the “test 
before treat” guidelines to reduce the amount of over-prescribing of anti-malarial medications? 
o Do you monitor prescribers for this? 
o What threats to ACT resistance have you noted? 
• Any additional comments on the topic?  
 
Practitioners 
• What local public health measures have been taken to reduce the prevalence of malaria? 
• When were these public health measures implemented locally? 
• How has this been done? 
• Do you feel there is widespread adoption in your area? How has the community reacted to these measures? 
• Have you identified any challenges or barriers in the community to use of these prevention methods? 
• What percentage of the community uses long lasting insecticide treated nets? 
• How often is indoor residual spraying insecticide used? 
• How do you measure the outcomes of these preventative measures? 
• Are there regions that you feel have not fully adopted these measures? 
• With emerging ACT resistance in other areas of the world, is there a “test before treat” policy to reduce the 
amount of over-prescribing of anti-malarial medications? 
• Do you have any additional comments on the topic? 
 
Community Health Workers:  
• What local public health measures have been taken to reduce the prevalence of malaria? 
• When were these public health measures implemented locally? 
• How has this been done? 
• Do you feel there is widespread adoption in your area? How has the community reacted to these measures?  
• What challenges or barriers have you found to their adoption of these methods? 
• What percentage of the community uses long lasting insecticide treated nets? 
• How often is indoor residual spraying insecticide used? 
• Do community members sell or use their insecticide treated nets in other ways? 
• Do you have any additional comments on the topic? 
 





Demographics of Key Informants 
Positions Nurse/ Community health workers on village health teams- 7 
Malaria prevention outreach workers- 1 
Practitioners: midwives, medical officers and emergency care practitioners- 6 
District Medical officer-1 
WHO officers-2 
Gender 7 Male 
10 Female  
Facilities  Masaka Referral Hospital 
Bukeeri Health Center III 
Buwungu health center II  
Kitabaazi Health Center II  
Malaria Action Programme for district office Plot 18, Matuba, Katwe, Butego, Masaka 
WHO office- Kampala 
Mpigi District Medical Office 




Community Adoption  Barriers and Challenges to this Prevention 
Strategy 
Long Lasting Insecticide 
Treated nets (LLINs) 
Majority of key informants estimated 70% 
coverage (although estimates range 
between 35-80%) 
 
They are free/ distributed from the 
government every 2 years 
(2014,2016,2018) 
•Supply chain issues 
•Tear easily, get old and not replaced 
frequently 
•Not used correctly (ie. most people sleep on 
the floor and when hung, the nets do not 
reach the floors. Some people do not sleep 
under them and believe that just hanging 
them will keep the mosquitos away) 
•Allergy to permethrin treatment 
•Itchy/ scratchy 
•Color of nets (2 years ago distributed blue 
nets which is associated with (Forum for 
Democratic Change, or FDC political party) 
•People feel they suffocate under the nets. 
•People get too hot under the nets. 
•Each family only typically has 1- so 
depending on sleeping arrangements many in 
the family do not get to use (usually give to 
younger children and typically leaving out 
teenage boys because they should be 
“tough”) 
•Cannot stand smell of the nets 
•Nets are misused (ie. keeping chickens 
fenced in, fencing in gardens, fishing, selling) 
Indoor Residual 
Insecticide Spraying (IRS) 
In general, this is not done in this area 
except in boarding schools because they do 
not allow insecticide treated nets.  
 
Key informants estimated between 0- 30% 
of homes use IRS 
Expensive, only being used in northern and 
eastern Uganda where there are epidemic 




Use sulfadoxine- pyramthamine (SP)- Starts 
at 13-20 weeks and given monthly in most 
areas. This guideline changed last year. 
Many pregnant women have difficulty 
obtaining transportation to the clinics for their 
prophylaxis. 
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Before that they were giving 3 doses during 
pregnancy. 
 
Key informants estimated between 50-
100% compliance 
 
Many are allergic to Sulfa 
 
If not directly observed, they will not take the 
medication.  
Intermittent preventive 
treatment: seasonal or in 
special populations 
(children under 5, patients 
with HIV, or Sickle cell 
disease)  
 
Sickle cell patients are given 
chemoprophylaxis (SP or chloroquine) 
monthly. 
Children are not given chemoprophylaxis 
but in most communities, they are given an 
insecticide treated net at their DPT 
vaccination. There is no seasonal 
chemoprophylaxis done here.  
Many are allergic to Sulfa 
Individual use of 
insecticide/ repellant  
Approximately 10-20% use  Expensive  
Rapid diagnosis Rapid diagnostic tests and microscopy 
used. 
 
In general, centers have good supply of 
RDT’s 
Lack of power- can only use microscopy by 
natural light and if it is cloudy or dark cannot 
use microscopy.  
Lack of technicians to use microscopy 
 
Delays in seeking treatment: Key informants 
note patients take 2-3 days to present after 
onset of fever. (ie. transportation issues, they 
feel they can get through it without medication 
even if they have malaria so they do not get 
tested) 
Treatment with ACT: 
(mostly Artemether + 
Lumefantrine used) 
All communities using ACT’s for treatment 
(twice daily for 3 days). 
Most follow “test before treat” policy but 
estimates between 0-40% patients with 
clinical symptoms of malaria are given 
antimalarial medications with antibiotics with 
a negative RDT or microscopy test with 
clinical signs of malaria.  
 
This medication tastes good.  
Although it is a short course most people will 
take only 2 days of their medications because 
they stop when they begin to feel better.  
 
People will use leftover anti-malarial 
medications when they or a family member 
spike a fever 
 
People are able to buy these medications at 
drug stores on their own so many take them 
as soon as they get a fever before being 
tested for malaria. 
 
Some do not believe they need treatment for 
malaria and it will “go away on its own” 
Education and screening 
within the community- 
using” Village Health 
Teams” or “Ready Home 
Teams” which consist of 
nurses and community 
health workers. 
“Group discussions” are done in the villages 
to educate 
 
Will go to homes and screen febrile children 
with rapid diagnostic tests and if positive, 
will treat. 
 
Many do not follow advice 
 
 
Due to lack of funding, there are less teams 
available 
Slashing bushes to 
reduce population of 
mosquitos near homes 
and planting (Omuteete or 
Teete) which is a 
citronella plant. 
 
 Many do not follow advice 
Reducing stagnant water 
to reduce breeding 
ground 
•Reduce bottles/ other 
trash that can hold 
stagnant water  
 Many do not follow advice 
 
Environmentally unfriendly 
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•Pour motor oil on 
stagnant water to 
suffocate mosquitos 
•Closing doors and 
windows before dusk (5 
pm) and use of wire mesh 
on windows to keep 
mosquitos out 
 Hot climate 
•Use of smoke/ fires 
around homes to 
decrease mosquitos  
 Poor air quality 
 
Table 2: Prevention strategies, community adoption and barriers based on community key informant interviews from 
the community (February 2019). 
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